Why the study?
Does genotype-guided antiplatelet therapy or universal ticagrelor improve cost-effectiveness compared to generic clopidogrel in patients aged 65 years with ACS undergoing PCI?
Does genotype-guided antiplatelet therapy or universal ticagrelor improve cost-effectiveness compared to generic clopidogrel in patients aged 65 years with ACS undergoing PCI?
Answers are grounded in this paper and cite their sources.
Genotype-guided personalization of antiplatelet therapy with ticagrelor is cost-effective, but treating all patients with ticagrelor is also an economically reasonable alternative in some settings.
Genotype-guided personalization may improve the cost-effectiveness of prasugrel and ticagrelor after percutaneous coronary intervention for ACS, but ticagrelor for all patients may bean economically reasonable alternative in some settings.
No takes yet. Share an insight, caveat, or question.
Kazi et al. (2014) studied Acute Coronary Syndrome (n=100,000). Prasugrel vs. Clopidogrel was evaluated on Quality-Adjusted Life-Years (QALYs) (ICER $35,800/QALY).
Synapse has enriched 10 related papers. Consider them for comparative context: